ArticleInternational journal of endocrinology2025
Bisphosphonate Therapy and the Occurrence of the Hungry Bone Syndrome After Surgery for Primary Hyperparathyroidism.
Article in International journal of endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Early parathyroid hormone elevation after denosumab therapy following parathyroidectomy: a diagnostic pitfall.JCEM case reports · 2026Article
- Preoperative Zoledronate Use and Risk of Postoperative Hypocalcemia After Parathyroidectomy for Primary Hyperparathyroidism: A Comparative Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Persistent calcium dependence after total thyroidectomy: a hypothesis of bone hunger syndrome with parathyroid reserve insufficiency in the setting of normalized parathyroid hormone - a case report and literature review.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hungry bone syndrome (HBS), marked by severe and persistent hypocalcemia, frequently occurs after parathyroidectomy for primary hyperparathyroidism (PHPT). Despite its prevalence, there is limited research on this complication. This study aimed to assess the impact of preoperative bisphosphonate treatment on the incidence of postoperative HBS in PHPT patients. Design: This retrospective study analyzed hospital records of patients with PHPT who underwent parathyroidectomy from January 2010 to January 2020. Patients: The study included 144 patients with PHPT who underwent curative parathyroidectomy at AL-Zahra University Hospital within the specified timeframe. Patients with secondary or tertiary hyperparathyroidism or unsuccessful surgeries were excluded. Measurements: Data on bisphosphonate use, clinical, and laboratory parameters were reviewed. Logistic regression analyzed the relationship between preoperative bisphosphonate treatment and the occurrence of postoperative HBS. Results: Of the total of 144 patients, 19 received preoperative bisphosphonate therapy. The incidence of HBS was significantly higher in the bisphosphonate group (57.9%) compared to the nontreated group (11.2%) ( Conclusion: Preoperative bisphosphonate therapy does not prevent the development of HBS following parathyroidectomy for PHPT. Continuous postoperative calcium monitoring is essential for effective management and mitigation of HBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.